Polaryx's PLX-200 Shows Promising Preclinical Results for Krabbe Disease — Polaryx Therapeutics, Inc.

Event summary

Polaryx presented preclinical data for PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026.
PLX-200 reduced astrogliosis, neuro-inflammation, and psychosine accumulation in Krabbe disease mouse models.
The SOTERIA trial, a Phase 2 open-label study, is set to begin in the first half of 2026.
Polaryx received FDA's safe-to-proceed letter in October 2025 for the SOTERIA trial.

The big picture

Polaryx's preclinical data for PLX-200 underscores the potential of repurposing gemfibrozil for rare lysosomal storage disorders. The upcoming SOTERIA trial represents a strategic pivot towards a flexible, resource-efficient approach to evaluate PLX-200's efficacy across multiple LSDs. The biotech sector is increasingly focusing on orphan drug development, and Polaryx's progress could position it as a key player in this niche market.

What we're watching

Trial Execution: The pace at which Polaryx initiates the SOTERIA trial will indicate its operational efficiency and readiness to advance PLX-200.
Regulatory Pathway: Whether the FDA's safe-to-proceed letter translates into smoother regulatory approvals for PLX-200.
Clinical Efficacy: How the preclinical success of PLX-200 in Krabbe disease translates into clinical outcomes across multiple LSDs.